Brean Capital analyst Jonathan Aschoff came out today with some commentary on OHR Pharmaceutical Inc (NASDAQ:OHRP), after the company reported initial, encouraging data for the treatment of retinal vein occlusion with OHR-102 at The American Society of Retina Specialists conference in Vienna last weekend. Aschoff reiterated a Buy rating on OHRP with a price target of $34, which implies an upside of 885% from current levels.
Aschoff wrote, “The limitations of the trial include its small size and therefore the difficulty of obtaining statistical significance. It will be more informative to see results from a much larger placebo controlled, multi-site trial where squalamine is given only to one trial arm for the entire duration. Although several other retinal vein occlusion trials involving anti-VEGF therapy (BRAVO, CRUISE, SHORE, COPERNICUS, GALILEO, VIBRANT) were much larger than this trial, this initial squalamine trial still compares favorably, and supports further development. We look forward near term to Ohr clarifying the design for its pivotal wet AMD trials, as well as next steps for squalamine in retinal vein occlusion.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 12.8% and a 56.7% success rate. Aschoff has a -57.8% average return when recommending OHRP, and is ranked #139 out of 3694 analysts.
Out of the 4 analysts polled by TipRanks, 3 rate OHR Pharmaceutical Inc stock a Buy, while 1 rates the stock a Hold. With a return potential of 521.2%, the stock’s consensus target price stands at $20.50.